UNITY BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.38 USD | -2.13% |
|
+6.15% | -28.50% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 331.2 | 277.3 | 84.28 | 38.89 | 32.39 | 23.17 | - | - |
| Enterprise Value (EV) 1 | 293.8 | 179.6 | 17.67 | -35.54 | -10.81 | 23.17 | 23.17 | 23.17 |
| P/E ratio | - | - | -1.34 x | -0.43 x | -0.71 x | -0.76 x | -0.69 x | -1.24 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 17.6 x | 165 x | - | - | - | 0.9 x |
| EV / Revenue | - | - | 17.6 x | 165 x | - | - | - | 0.9 x |
| EV / EBITDA | -3.81 x | -3.06 x | -1.57 x | -0.7 x | - | -0.71 x | -0.5 x | -0.49 x |
| EV / FCF | - | - | -18,62,274 x | -7,60,623 x | -8,73,203 x | - | - | - |
| FCF Yield | - | - | -0% | -0% | -0% | - | - | - |
| Price to Book | 2.82 x | 3.37 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,594 | 5,291 | 5,772 | 14,192 | 16,785 | 16,790 | - | - |
| Reference price 2 | 72.10 | 52.40 | 14.60 | 2.740 | 1.930 | 1.380 | 1.380 | 1.380 |
| Announcement Date | 11/03/20 | 23/03/21 | 15/03/22 | 15/03/23 | 15/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 4.784 | 0.236 | - | - | - | 25.72 |
| EBITDA 1 | -86.99 | -90.48 | -53.78 | -55.39 | - | -32.72 | -46.35 | -47.62 |
| EBIT 1 | -89.65 | -93.93 | -56.66 | -57.57 | -44.67 | -33.37 | -42.65 | -34.17 |
| Operating Margin | - | - | -1,184.47% | -24,394.92% | - | - | - | -132.81% |
| Earnings before Tax (EBT) 1 | - | - | -60.72 | -59.93 | -39.86 | -30.86 | -40.78 | -31.97 |
| Net income 1 | - | - | -60.72 | -59.93 | -39.86 | -30.86 | -40.78 | -31.97 |
| Net margin | - | - | -1,269.34% | -25,392.8% | - | - | - | -124.28% |
| EPS 2 | - | - | -10.90 | -6.310 | -2.700 | -1.826 | -1.992 | -1.113 |
| Free Cash Flow | - | - | -45.26 | -51.12 | -37.1 | - | - | - |
| FCF margin | - | - | -945.97% | -21,663.14% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/03/20 | 23/03/21 | 15/03/22 | 15/03/23 | 15/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.784 | - | 0.236 | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -7.372 | -7.85 | -8.463 | -9.127 |
| EBIT 1 | -9.898 | -18.27 | -12.26 | -13.13 | -13.92 | -10.65 | -11.96 | -14.93 | -7.677 | -7.599 | -8.072 | -8.578 | -9.119 |
| Operating Margin | -206.9% | - | -5,194.07% | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -10.69 | -18.92 | -13.14 | -13.71 | -14.17 | -10.86 | -12.2 | -15.29 | -4.339 | -5.79 | -7.833 | -8.35 | -8.885 |
| Net income 1 | -10.69 | -18.92 | -13.14 | -13.71 | -14.17 | -10.86 | -12.2 | -15.29 | -4.339 | -5.79 | -7.833 | -8.35 | -8.885 |
| Net margin | -223.52% | - | -5,566.53% | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.800 | -2.800 | -1.900 | -1.360 | -1.000 | -0.7600 | -0.8500 | -1.050 | -0.2800 | -0.3400 | -0.4620 | -0.4911 | -0.5206 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/03/22 | 10/05/22 | 12/08/22 | 08/11/22 | 15/03/23 | 09/05/23 | 08/08/23 | 13/11/23 | 15/04/24 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 37.5 | 97.7 | 66.6 | 74.4 | 43.2 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -45.3 | -51.1 | -37.1 | - | - | - |
| ROE (net income / shareholders' equity) | -58.4% | -92.3% | -85.3% | -94.8% | -94.4% | -197% | -196% | -65.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 25.60 | 15.60 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.59 | 0.65 | 0.2 | 0.1 | 0.01 | 0.65 | 0.65 | 0.65 |
| Capex / Sales | - | - | 4.08% | 40.68% | - | - | - | 2.53% |
| Announcement Date | 11/03/20 | 23/03/21 | 15/03/22 | 15/03/23 | 15/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.38
USD
Average target price
6
USD
Spread / Average Target
+334.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.50% | 2.32Cr | |
| +16.49% | 12TCr | |
| +21.73% | 12TCr | |
| +22.65% | 2.66TCr | |
| -21.81% | 1.99TCr | |
| -16.75% | 1.63TCr | |
| -18.81% | 1.55TCr | |
| -44.74% | 1.55TCr | |
| +62.72% | 1.48TCr | |
| +3.09% | 1.37TCr |
- Stock Market
- Equities
- UBX Stock
- Financials Unity Biotechnology, Inc.
